The FDA has accepted Ionis Pharmaceuticals' NDA for donidalorsen, an RNA-targeted medicine, for prophylactic treatment of hereditary angioedema (HAE).

A new CAR-T therapy is being trialed in the UK as a potential cure for lupus, an autoimmune condition affecting approximately 69,000 people in the UK.

Tenax Therapeutics has appointed Gillian Andor as Vice President of Clinical Operations to support its Phase 3 program for oral levosimendan (TNX-103).

The UK government has launched the Dementia Trials Accelerator (DTA) with £20 million in funding to increase participation in dementia clinical trials.

MicuRx announced positive results from its Phase 1 clinical trial of MRX-5, an oral antibacterial agent targeting nontuberculous mycobacterial (NTM) infections.

Lyell Immunopharma is presenting initial Phase 1-2 clinical data for IMPT-314, a dual-targeting CAR T-cell therapy, at the ASH Annual Meeting.

Eli Lilly's mirikizumab demonstrates long-term efficacy in both ulcerative colitis (UC) and Crohn's disease, marking it as the first IL-23p19 antagonist with multi-year sustained results.

The FDA granted accelerated approval to Ziihera (zanidatamab-hrii) for previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC).

The FDA granted accelerated approval to Ziihera (zanidatamab-hrii) for previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC).

Astria Therapeutics is initiating the ALPHA-ORBIT Phase 3 trial to evaluate navenibart for hereditary angioedema (HAE) with flexible dosing.

Gilead's lenacapavir demonstrated near-perfect efficacy as a twice-yearly injectable for HIV PrEP in Phase III trials, offering a promising alternative to daily oral treatments.

Clinical Trial Media (CTM) achieved 62% diverse participant randomization in an Alzheimer's Disease trial, where the condition is most prevalent among Black and Hispanic women.

ProJenX has formed a Clinical Advisory Board (ClAB) comprising experts in ALS clinical trial design to guide the development of prosetin.

Blood tests are emerging as a less invasive and more accessible method for diagnosing Alzheimer's disease, potentially leading to earlier treatment and intervention.

Tel Aviv University researchers have developed a groundbreaking method to deliver mRNA-based drugs directly to inflamed intestines while bypassing the liver, potentially revolutionizing IBD treatment.

University of Basel researchers demonstrate Angle's Parsortix system can capture over 99% of circulating tumor cell clusters from blood samples, enabling breakthrough metastasis prevention research.

The National University of Singapore and Cerner Enviza have collaborated on Project Golden Years, investigating evolving attitudes towards dementia prevention in Singapore through real-world qualitative research.

Late-breaking results from the CLEAR OASIS 9 trial reveal that colchicine failed to reduce cardiovascular events after myocardial infarction despite lowering inflammatory markers.

The Research Institute of McGill University Health Centre (RI-MUHC) has initiated a global Phase 1 clinical trial for Actinium-225, a novel treatment targeting metastatic prostate cancer. This trial, led by Dr. Ramy Saleh, aims to evaluate the safety and tolerability of Actinium-225, which targets the prostate-specific membrane antigen (PSMA) to kill cancer cells while sparing healthy organs. The study represents a significant advancement in precision medicine for patients who have exhausted other treatment options.

Cordis has initiated the SELUTION Global Coronary Registry, which will track real-world outcomes of their sirolimus-eluting balloon in up to 10,000 patients worldwide for five years.